NDC 50419-524-01 - Betaseron

This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.

Product NDC: 50419-524
Requested NDC: 50419-524-01
Package NDCs from labels: 50419-524-01, 50419-524-35, 50419-524-05, 50419-524-09, 50419-524-81
Manufacturer: Bayer HealthCare Pharmaceuticals Inc.
Effective date: 2026-03-03
Current FDA listing: Not matched in FDA.report NDC product tables

DailyMed Labels#

Label, Manufacturer, Effective date table
Label	Manufacturer	Effective date	Type
Betaseron - Bayer HealthCare Pharmaceuticals Inc.	Bayer HealthCare Pharmaceuticals Inc.	2026-03-03	HUMAN PRESCRIPTION DRUG LABEL

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDC	Effective	Related label
50419-524-05	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-08-20	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-07-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-05	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-09	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-35	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993
50419-524-81	2024-01-30	These highlights do not include all the information needed to use BETASERON safely and effectively. See full prescribing information for BETASERON. BETASERON (interferon beta-1b) for injection, for subcutaneous use Initial U.S. Approval: 1993

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
50419-524-01	Betaseron	1 in 1 CARTON	KIT	1	29
50419-524-05	Betaseron	5 in 1 BOX	KIT	5	29
50419-524-09	Betaseron	1 in 1 BOX	KIT	1	29
50419-524-35	Betaseron	14 in 1 BOX	KIT	14	29
50419-524-81	Betaseron	14 in 1 BOX	KIT	14	29

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
50419-524	BETASERON (INTERFERON BETA-1B) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]	23	Current NDC, Legacy NDC, 5 package rows	20240821_66311f74-0472-4fa3-848a-06002ca0def5.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
50419-524-01	EA - Each	50419-524	c38dd881-23ee-4f5a-b0a7-f7ea716f041f	1	2013-12-02
50419-524-35	EA - Each	50419-524	bfbe2cc2-fb88-4a78-8415-f62752bf93e5	1	2013-12-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
INTERFERON BETA-1B	ACTIVE INGREDIENT	TTD90R31WZ	BETASERON (INTERFERON BETA-1B) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]	3
INTERFERON BETA-1B	ACTIVE MOIETY	TTD90R31WZ	BETASERON (INTERFERON BETA-1B) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]	3
ALBUMIN HUMAN	INACTIVE INGREDIENT	ZIF514RVZR	BETASERON (INTERFERON BETA-1B) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]	3
MANNITOL	INACTIVE INGREDIENT	3OWL53L36A	BETASERON (INTERFERON BETA-1B) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]	3
SODIUM CHLORIDE	INACTIVE INGREDIENT	451W47IQ8X	BETASERON (INTERFERON BETA-1B) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]	3

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 5 of 44 · 870 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Thyroid HP	BARYTA CARBONICA, CALCAREA CARBONICA, FUCUS VESICULOSUS, IODIUM, NATRUM MURIATICUM, PULSATILLA, SPONGIA TOSTA, THYROIDINUM (SUIS)	BioActive Nutritional, Inc.	3795820a-cf2a-4094-9a02-70e3757b7510	2026-04-17	Warnings	Exact identifier unii: 451W47IQ8X
DIANEAL Low Calcium with Dextrose	SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE	Vantive US Healthcare LLC	aa268d3f-7389-4f25-801f-5d4825495f08	2026-04-16	Warnings, Adverse reactions	Exact identifier unii: 451W47IQ8X
PEG 3350 and Electrolytes	POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE	Wilshire Pharmaceuticals, Inc.	b251752d-7750-482a-9364-0acf4ad47cc8	2026-04-16	Warnings, Adverse reactions	Exact identifier unii: 451W47IQ8X
Dextrose and Sodium Chloride	DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE	Fresenius Kabi USA, LLC	99c6a1a9-cadf-435b-a332-ccc189afdfa9	2026-04-16	Warnings, Adverse reactions	Exact identifier unii: 451W47IQ8X
GoLYTELY	POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE	Azurity Pharmaceuticals, Inc.	7609ecf7-0ce0-4fbb-9c27-30987f689575	2026-04-15	Warnings, Adverse reactions	Exact identifier unii: 451W47IQ8X
TRILYTE	POLYETHYLENE GLYOCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE AND POTASSIUM CHLORIDE	Aurobindo Pharma Limited	79f5e596-8d51-4227-afcc-f5e341150957	2026-04-15	Warnings, Adverse reactions	Exact identifier unii: 451W47IQ8X
Anxiety Relief	ACONITUM NAPELLUS, ARGENTUM NITRICUM, ARSENICUM ALBUM, AURUM METALLICUM, GELSEMIUM SEMPERVIRENS, HYOSCYAMUS NIGER, IGNATIA AMARA, KALI CARBONICUM, MOSCHUS, NATRUM MURIATICUM, PIPER METHYSTICUM	NaturalCare	9f982e89-655c-49be-85d8-4099a02ed021	2026-04-15	Warnings	Exact identifier unii: 451W47IQ8X
PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride	POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE	Wilshire Pharmaceuticals, Inc.	4e442a72-b13b-4869-8a1d-59356095b091	2026-04-14	Warnings, Adverse reactions	Exact identifier unii: 451W47IQ8X
SODIUM CHLORIDE 1 GRAM	SODIUM CHLORIDE	Gendose Pharmaceuticals, LLC	ce988ae5-61c6-4324-90e1-a94c8a54d0d0	2026-04-13	Warnings	Exact identifier unii: 451W47IQ8X
Quantum Resonance	ALCOHOLUS, ALUMINA SILICATA, ANACARDIUM ORIENTALE, AQUA MARINA, BAPTISIA TINCTORIA, CANDIDA ALBICANS, COLLAGEN, DNA, LAVANDULA OFFICINALIS, MEDULLA OSSIS SUIS, NATRUM MURIATICUM, NATRUM PHOSPHORICUM, NUX MOSCHATA, PHOSPHORUS, QUARTZ, SILICEA, TELA ARANEA, VALERIANA OFFICINALIS, VISCUM ALBUM	Deseret Biologicals, Inc.	f94a10bd-1c40-42c7-b458-b58070614549	2026-04-10	Warnings	Exact identifier unii: 451W47IQ8X
Quantum Resonance	ALCOHOLUS, ALUMINA SILICATA, ANACARDIUM ORIENTALE, AQUA MARINA, BAPTISIA TINCTORIA, CANDIDA ALBICANS, COLLAGEN, DNA, LAVANDULA OFFICINALIS, MEDULLA OSSIS SUIS, NATRUM MURIATICUM, NATRUM PHOSPHORICUM, NUX MOSCHATA, PHOSPHORUS, QUARTZ, SILICEA, TELA ARANEA, VALERIANA OFFICINALIS, VISCUM ALBUM	Deseret Biologicals, Inc.	1467111a-bef6-473d-b7f2-3309a9bb72ce	2026-04-10	Warnings	Exact identifier unii: 451W47IQ8X
H-Focus Formula	AGNUS CASTUS, AVENA SATIVA, BARYTA CARBONICA, IGNATIA AMARA, LYCOPODIUM CLAVATUM, NATRUM CARBONICUM, NATRUM MURIATICUM, PHOSPHORICUM ACIDUM, SILICEA, ZINCUM METALLICUM	Healing Natural Oils LLC	4ee42911-3064-7f55-e063-6294a90abcc7	2026-04-07	Warnings	Exact identifier unii: 451W47IQ8X
H-Mood Formula	AGRIMONIA EUPATORIA, FLOS, ANACARDIUM ORIENTALE, AURUM METALLICUM, AVENA SATIVA, BORAGO OFFICINALIS, CAPSICUM ANNUUM, CARPINUS BETULUS, FLOS, CIMICIFUGA RACEMOSA, CINCHONA OFFICINALIS, HYPERICUM PERFORATUM, KALI BROMATUM, LARIX DECIDUA, FLOS, NATRUM CARBONICUM, NATRUM MURIATICUM, NATRUM SULPHURICUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, PULSATILLA, SILICEA, SINAPSIS ARVENSIS, FLOS, TABACUM	Healing Natural Oils LLC	4ee5c82e-9edf-c36e-e063-6394a90a237f	2026-04-07	Warnings	Exact identifier unii: 451W47IQ8X
Walgreens Sodium Chloride Ophthalmic 5 Percent Hypertonicity Eye	SODIUM CHLORIDE	Walgreen Company	bda3b9db-5fc4-408c-a5ae-d1eeb3ee308d	2026-04-06	Warnings	Exact identifier unii: 451W47IQ8X
Sodium Chloride Ophthalmic 5 Percent Hypertonicity Eye	SODIUM CHLORIDE	Hanlim	4ee80e16-1bb1-8238-e063-6294a90aa719	2026-04-04	Warnings	Exact identifier unii: 451W47IQ8X
BACTERIOSTATIC SODIUM CHLORIDE	SODIUM CHLORIDE	Hospira, Inc.	376093e7-e09e-4a57-3199-195e45251866	2026-04-03	Boxed warning, Warnings, Adverse reactions	Exact identifier unii: 451W47IQ8X
Migraine and Headache	IRIS VERSICOLOR ROOT AND SODIUM CHLORIDE	Forces of Nature	0dd2f2e2-78e2-435e-b7b2-ca590953ff94	2026-04-01	Warnings	Exact identifier unii: 451W47IQ8X
Cold Sore Formula	DULCAMARA, GLYCYRRHIZA GLABRA, RANUNCULUS BULBOSUS, RHUS TOX, NATRUM MURIATICUM, FAGOPYRUM ESCULENTUM, NATRUM MURIATICUM, ACONITUM NAPELLUS, CYTOMEGALOVIRUS NOSODE, HERPES SIMPLEX I AND II NOSODE, SEPIA, EPSTEIN BARR VIRUS NOSODE, HERPES ZOSTER NOSODE, ADENOVIREN NOSODE	Nutritional Specialties, Inc.	f4e7e469-baaf-4c61-af44-80b0832eadf0	2026-03-31	Warnings	Exact identifier unii: 451W47IQ8X
Sodium Chloride Normal Salt	SODIUM CHLORIDE	TWIN MED LLC	10230c8a-e5e5-44f1-b41d-80930899d6b9	2026-03-31	Warnings	Exact identifier unii: 451W47IQ8X
H-Allergy Formula	ALLIUM CEPA, AMBROSIA ARTEMISIAEFOLIA, ARUM TRIPHYLLUM, ARUNDO MAURITANICA, EUPHRASIA OFFICINALIS, GALPHIMIA GLAUCA, HISTAMINUM HYDROCHLORICUM, KALI BICHROMICUM, NATRUM MURIATICUM, SOLIDAGO VIRGAUREA, STICTA PULMONARIA, SULPHUR, TRIFOLIUM PRATENSE, WYETHIA HELENIOIDES	Healing Natural Oils LLC	4e586360-b3c4-1ce0-e063-6394a90ab6b8	2026-03-31	Warnings	Exact identifier unii: 451W47IQ8X

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.